Tear film and ocular surface alterations in chronic users of antiglaucoma medications;Alteração do filme lacrimal e superfície ocular em usuários crônicos de medicação antiglaucomatosa

Arquivos Brasileiros de Oftalmologia

Volumn 71, Issue 1, 2008, Pages 18-21

  Baffa, Lina do Prado ^a   da Silva Ricardo, Jose Reinaldo ^a   Dias, Ana Carolina ^a   Módulo, Carolina Maria ^a   Braz, Alexandre Martins ^a   de Paula, Jayter Silva ^a   Veronese Rodrigues, Maria de Lourdes ^a   Rocha, Eduardo Melani ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Benzalkonium compounds administration and dosage; Benzalkonium compounds drug effects; Dry eye syndromes; Glaucoma drug therapy; Indicators and reagents; Optic disk drug effects; Tears drug effects; Timolol administration and dosage; Timolol drug effects

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRINZOLAMIDE; PILOCARPINE; SULFONAMIDE; THIAZINE DERIVATIVE;

ARTICLE; CASE CONTROL STUDY; DRUG EFFECT; FEMALE; GLAUCOMA; HOSPITALIZATION; HUMAN; LACRIMAL APPARATUS; LACRIMAL FLUID; MALE; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE;

ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; GLAUCOMA; HUMANS; LACRIMAL APPARATUS; MALE; MIDDLE AGED; PILOCARPINE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TEARS; THIAZINES;

EID: 58849125845     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492008000100004     Document Type: Article

References (25)

1. Goto E, Yagi Y, Matsumoto Y, Tsubota K. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133(2):181-6.
2. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol. 1995;13:307-38.
3. Rieger G. The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol. 1992;76(3):157-8.
4. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18(5):401-9.
5. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucomatous medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-54.
6. Comment in: Arch Ophthalmol. 1995;113(7):849-50.
7. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437-45.
8. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-23.
9. de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232(4):221-4.
10. Ohtsuki M, Yokoi N, Mori K, Matsumoto Y, Adachi W, Ishibashi K, et al. [Adverse effects of beta-blocker eye drops on the ocular surface]. Nippon Ganka Gakkai Zasshi. 2001;105(3):149-54. Japanese.
11. Kuppens EV, van Best JA, Sterk CC, de Keizer RJ. Decreased basal tear turnover in patients with untreated primary open-angle glaucoma. Am J Ophthalmol. 1995;120(1):41-6.
12. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45(5):1360-8.
13. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082-8.
14. Shimazaki J, Hanada K, Yagi Y, Yamagami J, Ishioka M, Shimmura S, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone. Br J Ophthalmol. 2000;84(11):1250-4.
15. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21(4):221-32.
16. Barros JN, Mascaro VL, Gomes JA, Freitas D, Lima, ALH. Citologia de impressão de superficie ocular: técnica de exame e de coloração. Arq Bras Oftalmol. 2001;64(2):127-31.
17. Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44(11):4753-61.
18. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Cornea. 1998;17(6):574-83.
19. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology. 2002;109(11):1955-6.
20. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology. 1992;99(6):873-8.
21. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica. 2002;216(3):175-9.
22. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111(12):2186-92.
23. Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis. 1998;57(1):20-4.
24. Lucca JA, Nunez JN, Farris RL. A comparison of diagnostic tests for keratoconjunctivitis sicca: lactoplate, Schirmer, and tear osmolarity. CLAO J. 1990;16(2):109-12.
25. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998; 105(6):1114-9.